Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
No Early Relief for JW Therapeutics from Cancer Wonder Drug
The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices…
RELATED ARTICLES
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Sunshine tries out asset leasing as insurance demand cools
6963.HK 3396.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
